Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy

Journal of the American Society of Nephrology

Volumn 23, Issue 5, 2012, Pages 814-824

  Serino, Grazia ^a,b   Sallustio, Fabio ^a,b   Cox, Sharon N ^a   Pesce, Francesco ^a   Schena, Francesco P ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b Centro Addestramento Ricerca Scientifica in Oncologia (CARSO) Consortium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORE 1, BETA1,3 GALACTOSYLTRANSFERASE 1; CREATININE; GALACTOSYLTRANSFERASE; IMMUNOGLOBULIN A1; MICRORNA; MICRORNA 148B; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; ANAPHYLACTOID PURPURA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; EX VIVO STUDY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SYSTOLIC BLOOD PRESSURE;

EID: 84860609648     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011060567     Document Type: Article

References (49)

1. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8: 199-207, 1997 (Pubitemid 127455874)
2. Schena FP, Coppo R: IgA nephropathies. In: Oxford Textbook of Clinical Nephrology, 3rd ed., edited by Davison AM, Cameron JS, Grünfeld JP, Ponticelli C, Ritz E, Winearls CG, van T Persele C, Oxford, Oxford University Press, 2005, pp 469-501
3. Conley ME, Cooper MD, Michael AF: Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66: 1432-1436, 1980 (Pubitemid 11205607)
4. Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 16: 2088-2097, 2005 (Pubitemid 41716440)
5. Coppo R, Amore A: Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 65: 1544-1547, 2004 (Pubitemid 38590997)
6. Novak J, Julian BA, Tomana M, Mesteck J: Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol 21: 310-327, 2001 (Pubitemid 33015802)
7. Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, Kobayashi Y: Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 9: 2048-2054, 1998 (Pubitemid 28482152)
8. Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J: Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52: 509-516, 1997 (Pubitemid 27359597)
9. Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J: Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104: 73-81, 1999 (Pubitemid 29534347)
10. Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S: Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 104: 172-182, 1993
11. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcón GS, Kimberly RP, Tomino Y, Mestecky J, Novak J: IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118: 629-639, 2008 (Pubitemid 351206552)
12. Eijgenraam JW, van Kooten C: IgA1 glycosylation in IgA nephropathy: As sweet as it can be. Kidney Int 73: 1106-1108, 2008 (Pubitemid 351620429)
13. Buck KS, Smith AC, Molyneux K, El-Barbary H, Feehally J, Barratt J: B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int 73: 1128-1136, 2008 (Pubitemid 351620426)
14. Qin W, Zhou Q, Yang LC, Li Z, Su BH, Luo H, Fan JM: Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med 258: 467-477, 2005 (Pubitemid 41546563)
15. Beerman I, Novak J, Wyatt RJ, Julian BA, Gharavi AG: The genetics of IgA nephropathy. Nat Clin Pract Nephrol 3: 325-338, 2007 (Pubitemid 46834885)
16. Lai AS, Lai KN: Molecular basis of IgA nephropathy. Curr Mol Med 5: 475-487, 2005 (Pubitemid 41086773)
17. Cox SN, Sallustio F, Serino G, Pontrelli P, Verrienti R, Pesce F, Torres DD, Ancona N, Stifanelli P, Zaza G, Schena FP: Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int 78: 396-407, 2010
18. Kudo T, Iwai T, Kubota T, Iwasaki H, Takayma Y, Hiruma T, Inaba N, Zhang Y, Gotoh M, Togayachi A, Narimatsu H: Molecular cloning and characterization of a novel UDP-Gal:GalNAc(alpha) peptide beta 1,3-galactosyltransferase (C1Gal-T2), an enzyme synthesizing a core 1 structure of O-glycan. J Biol Chem 277: 47724-47731, 2002 (Pubitemid 36159296)
19. Kato M, Arce L, Natarajan R: MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 4: 1255-1266, 2009
20. Barratt J, Smith AC, Molyneux K, Feehally J: Immunopathogenesis of IgAN. Semin Immunopathol 29: 427-443, 2007 (Pubitemid 350077260)
21. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F, Foramitti M, Ravani P, Roccatello D, Savoldi S, Cerullo G, Lanzilotta SG, Bisceglia L, Zelante L, Floege J, Alexopoulos E, Kirmizis D, Ghiggeri GM, Frascà G, Schena FP, Amoroso A European IgAN Consortium: Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol 22: 152-159, 2009
22. LiGS, Zhang H, Lv JC, Shen Y, Wang HY: Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 71: 448-453, 2007
23. Ju T, Cummings RD: A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β 3-galactosyltransferase. Proc Natl Acad Sci USA 99: 16613-16618, 2002 (Pubitemid 36034021)
24. Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, Emancipator SN, Tomino Y: Down-regulation of core 1 beta1,3- galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 25: 3890-3897, 2010
25. Julian BA, Waldo FB, Rifai A, Mestecky J: IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med 84: 129-132, 1988
26. Julian BA, Novak J: IgA nephropathy: An update. Curr Opin Nephrol Hypertens 13: 171-179, 2004 (Pubitemid 38373139)
27. Allen AC, Topham PS, Harper SJ, Feehally J: Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant 12: 701-706, 1997 (Pubitemid 27170423)
28. Anglicheau D, Sharma VK, Ding R, Hummel A, Snopkowski C, Dadhania D, Seshan SV, Suthanthiran M: MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci USA 106: 5330-5335, 2009
29. Te JL, Dozmorov IM, Guthridge JM, Nguyen KL, Cavett JW, Kelly JA, Bruner GR, Harley JB, Ojwang JO: Identification of unique microRNA signature associated with lupus nephritis. PLoS ONE 5: e10344, 2010
30. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, Iacomini J: Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci USA 107: 14339-14344, 2010
31. Wang G, Kwan BC, Lai FM, Choi PC, Chow KM, Li PK, Szeto CC: Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab Invest 90: 98-103, 2010
32. Allen AC, Harper SJ, Feehally J: Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 100: 470-474, 1995
33. Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J: Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60: 969-973, 2001 (Pubitemid 34205796)
34. Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K: Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59: 1077-1085, 2001 (Pubitemid 32206870)
35. Roccatello D, Picciotto G, Torchio M, Ropolo R, Ferro M, Franceschini R, Quattrocchio G, Cacace G, Coppo R, Sena LM, et al: Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Lab Invest 69: 714-723, 1993 (Pubitemid 24026852)
36. Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J: IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 67: 504-513, 2005 (Pubitemid 40139842)
37. Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, Vrtovsnik F, Haddad E, Chintalacharuvu KR, Monteiro RC: Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 15: 622-634, 2004 (Pubitemid 38294792)
38. Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, Lepelletier Y, Vrtovsnik F, Haddad E, Benhamou M, Monteiro RC: Engagement of transferrin receptor by polymeric IgA1: Evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 16: 2667-2676, 2005
39. Peppard JV, Kaetzel CS, Russell MW: Phylogeny and comparative physiology of IgA. In: Mucosal Immunology, 3rd ed., edited by Mestecky J, Bienenstock J, Lamm, ME, Mayer L, McGhee JR, Strober W, Academic Press, Burlington, MA, 2005, pp 195-210
40. Mestecky J, Moro I, Kerr MA, Woof JM: Mucosal immunoglobulins. In: Mucosal Immunology, 3rd ed., edited by Mestecky J, Bienenstock J, Lamm, ME, Mayer L, McGhee JR, Strober W, Academic Press, Burlington, MA, 2005, pp 153-181
41. Manno C, Strippoli GF, D'Altri C, Torres D, Rossini M, Schena FP: A novel simpler histological classification for renal survival in IgA nephropathy: A retrospective study. Am J Kidney Dis 49: 763-775, 2007 (Pubitemid 46802935)
42. Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100: 9440-9445, 2003 (Pubitemid 37033947)
43. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ: miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34[Database issue]: D140-D144, 2006
44. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009
45. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005 (Pubitemid 40617277)
46. Barenboim M, Zoltick BJ, Guo Y, Weinberger DR: MicroSNiPer: A web tool for prediction of SNP effects on putative microRNA targets. Hum Mutat 31: 1223-1232, 2010
47. Steinitz M, Klein G: EBV-transformation of surface IgA-positive human lymphocytes. J Immunol 125: 194-196, 1980 (Pubitemid 10040421)
48. Moore JS, Kulhavy R, Tomana M, Moldoveanu Z, Suzuki H, Brown R, Hall S, Kilian M, Poulsen K, Mestecky J, Julian BA, Novak J: Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol 44: 2598-2604, 2007 (Pubitemid 46240321)
49. Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J: Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71: 1148-1154, 2007 (Pubitemid 46809135)